|Tested species reactivity||Human, Non-human primate|
|Published species reactivity||Not Applicable|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Purified recombinant fragment of BTK expressed in E. Coli.|
|Contains||0.03% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Immunofluorescence (IF)||1/200 - 1/1000|
|Immunohistochemistry (IHC)||1/200 - 1/1000|
|Western Blot (WB)||1/500 - 1/2000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (IHC)||See 1 publications below|
MA5-15337 targets BTK in IF, IHC, and WB applications and shows reactivity with Human and Non-human primate samples.
The MA5-15337 immunogen is purified recombinant fragment of BTK expressed in E. Coli.
MA5-15337 detects BTK which has a predicted molecular weight of approximately 77kDa.
The protein encoded by this gene plays a crucial role in B-cell development. Mutations in this gene cause X-linked agammaglobulinemia type 1, which is an immunodeficiency characterized by the failure to produce mature B lymphocytes, and associated with a failure of Ig heavy chain rearrangement.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Comprehensive phenotypic characterization of PTLD reveals potential reliance on EBV or NF-¿B signalling instead of B-cell receptor signalling.
MA5-15337 was used in immunohistochemistry to evaluate the reliance on EBV or NF-kappaB signaling instead of B-cell receptor signaling in regards to complete phenotypic characterization of PTLD
|Menter T,Dickenmann M,Juskevicius D,Steiger J,Dirnhofer S,Tzankov A||Hematological oncology (null:null)||2016|